Protalix Biotherapeutics in Milano on Monday 23rd January 2023. Attending Management: Eyal Rubin | Chief Financial Officer
Company Snapshot: PROTALIX BIOTHERAPEUTICS (PLX) (NYSE:PLX) $1.55 on January 10th, 2023 45,56 Million shares issued & outstanding Market Cap = $71M; Cash Runway into 3Q23 Convertible Notes: $28.7M due Sep. 2024 $1B+ in Milestone payments and 15-40% Royalties on PRX-102 Summary: Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through…